Introduction
============

Ischemic heart disease (IHD), also called coronary artery disease (CAD) ([@B45]), refers to the condition of stenosis or obstruction of the lumen of arteries and inadequate blood supply to the myocardium leading to myocardial ischemia (MI), hypoxia or necrosis. Clinically, IHD includes asymptomatic MI, angina, myocardial infarction, ischemic heart failure and sudden cardiac death ([@B80]). IHD is reported to be the leading reason of disability and death worldwide which caused 8.9 million deaths in 2015, resulting in a large economic burden to the medical community ([@B34]). Although several risk factors including high blood pressure, smoking, diabetes, lack of exercise, obesity and high blood cholesterol have been identified ([@B12]; [@B59]), the therapeutic effects are still limited. Therefore, new treatment strategies mitigating the deleterious effects of IHD are being explored intensively. Growing evidence suggest the potential pro-angiogenic benefits of Chinese herbal medicines in IHD. This review will summarize the status and process of the pro-angiogenic roles and mechanism of Chinese herbal medicines in IHD. In addition, the limitations and future challenges will be highlighted.

Methodology
===========

The United States National Library of Medicine, National Institutes of Health (NIH) database^[1](#fn01){ref-type="fn"}^ was searched with the terms "IHD" or "therapeutic angiogenesis" or "Chinese herbal medicines" in the "title/abstract" field. Related articles were chosen manually before 31st December, 2017. All articles which had an abstract available were included. No language restrictions were applied.

Treatment Status of Ischemic Heart Disease
==========================================

The front line clinical treatments for IHD include drug therapy, percutaneous coronary intervention (PCI) and coronary artery bypass grafts (CABGs). There are a number of pharmaceutical therapies which are widely used in IHD including nitroglycerin ([@B8]), statins ([@B37]), β-blockers ([@B7]), and calcium channel blockers ([@B18]) but their beneficial effects are limited. In some cases symptoms are still are not significantly improved even upon maximal dosage of drug therapy ([@B65]). PCI is a minimal invasive procedure to treat stenosis of the coronary arteries. A deflated balloon catheter is advanced into an obstructed artery via the saphenous or radial artery. Inflation of the balloon reverses the narrowing of the blood vessel ([@B64]). Alternatively, stents are placed in the narrowed artery to ensure blood vessels remain dilated. PCI is restricted to patients whose angiography do not show arteries \<1.5 mm in diameter or display diffusely diseased saphenous vein grafts ([@B61]). CABG is a surgical strategy to improve the coronary perfusion and used to treat patients who have severe IHD. During this process, sections of saphenous vein and radial artery are usually used as the vascular bridge. The blood bypasses the lesion of coronary artery and flows to the ischemic myocardium through the vascular bridge. However, the patency of the grafted artery or vein depends on the patient's vascular status and is likely to be atherosclerotic similar to the coronary vessels. Furthermore, due to the invasive nature it is not a viable procedure in elderly patients, e.g., octogenarians and above ([@B63]). Approximately 12% of patients with IHD are unsuited to the classical PCI or CABG treatment ([@B75]). This is due to diffuse disease, chronic total occlusion, multiple stenosis, poor targets and severe comorbidities ([@B60]). Therapeutic angiogenesis has attracted great interest in targeting patients that are not viable for the current treatment. Increasing blood supply to the ischemic zone is fundamental to the treatment of IHD. Therefore, therapeutic angiogenesis is the promising approach aimed at returning cardiac function ([@B69]; [@B49]). The applications of growth factor therapy, gene therapy and stem cell therapy are becoming more widely used.

Recent findings have indicated that Chinese herbal medicines may be effective in the treatment of IHD by promoting angiogenesis. Focus has turned to pre-clinical investigations to understand the mechanism in which Chinese herbal medicines can induce angiogenesis in IHD. In this review, we summarize current data on the pro-angiogenic role of Chinese herbal medicines in IHD. The review focuses on the research process and prospects of traditional Chinese herbal medicines in therapeutic angiogenesis for IHD.

Basic Mechanisms of Angiogenesis
================================

Three important processes are required for the development of the vascular system, vascular network formation during embryonic development (vasculogenesis) ([@B70]), microvascular formation (angiogenesis) ([@B5]; [@B10]) and the formation of larger arteries and vessels (arteriogenesis) ([@B40]). Neovascularization is a term used to describe vessel development ([@B30]).

Angiogenesis refers to the development of new blood vessels from pre-existing capillaries ([@B3]). The process of angiogenesis includes degradation of vascular basement membrane; proliferation and migration of endothelial cells; lumen structure and vascular network formation ([@B68]). The mechanism of angiogenesis is complicated and tightly regulation of different cell types, such as endothelial cells, smooth muscle cells, and inflammatory cells. Vascular endothelial cells have the ability of rapid proliferation, migration and differentiation in response to physiological stimulation ([@B29]). There are many molecules involved in the regulation of angiogenesis, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), transforming growth factor (TGF), tumor necrosis factor (TNF) and angiopoietin-2, etc. VEGF is the most studied, and a large number of pre-clinical experiments have proved that it is effective in promoting angiogenesis. VEGF can activate a plethora of downstream pathways including PI3K-Akt/mTORC2 pathway, Raf-MEK-MAPK pathway and Src-FAK pathway ([@B57]; [@B17]) (**Figure [1](#F1){ref-type="fig"}**). Tissue hypoxia or inflammation is major stimuli of angiogenesis. In settings where angiogenesis is deficient administration of recombinant proteins, or gene and stem cells therapies can enhance the ability for angiogenesis to occur.

![VEGF signaling pathway involved in angiogenesis.](fphar-09-00428-g001){#F1}

Ischemic Heart Disease and Angiogenesis
=======================================

Angiogenic Growth Factor Therapy
--------------------------------

Ischemic heart disease is caused by the stenosis or obstruction of coronary blood vessels denying oxygen to the heart muscle. Promoting the heart to generate new blood vessels through angiogenesis provides a potential to combat IHD. Over the last few decades this has been attempted mainly through the delivering cytokines to increase blood perfusion in the ischemic region and ultimately reverse the disease ([@B19]). Traditional cytokine-based therapies, such as VEGF, FGF, platelet-derived growth factor (PDGF) and angiopoietins, have shown theoretical and experimental promises for treating ischemic diseases ([@B39]; [@B4]).

### Vascular Endothelial Growth Factors

To date, VEGF is a recognized regulator of angiogenesis and is an endothelial specific mitogen for IHD. The VEGF family comprises of different isoforms, VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PIGF) ([@B62]). VEGF frequently refers to VEGF-A. VEGF-A contributes to angiogenesis, vasculogenesis, and vascular homeostasis. In contrast to VEGF-A, VEGF-B can't regulate angiogenesis and it functions in the muscle fatty acids uptake ([@B58]). In addition, VEGF-C and VEGF-D regulate the lymph system and adipose tissue inflammation ([@B46]). PIGF is synthesized mainly by trophoblast cells and can bind to tyrosinase receptors in trophoblast cells and vascular endothelial cells. PIGF mainly affects the function of trophoblast cells through autocrine action, and influences the process of vascular growth through paracrine action ([@B9]). The receptors of VEGFs include VEGFR1 (Flt1), VEGFR2 (Flk1), and VEGFR3. VEGF can promote the proliferation, migration, and angiogenesis of endothelial cells by promoting the mitochondria function ([@B35]). It was shown in porcine coronary occlusion model that VEGF treatment increased blood flow and recovery of cardiac function ([@B39]). Intracoronary VEGF treatment enhanced the development of small coronary arteries supplying ischemic myocardium in dogs ([@B6]). However, there are many limitations in the administration of VEGF. VEGF may induce the progression of atherosclerotic plaques ([@B11]). What's worse, VEGF over-loading has the potential to cause cancer ([@B38]), diabetic retinopathy ([@B1]), and rheumatoid arthritis ([@B28]).

### Fibroblastic Growth Factors

Fibroblastic growth factors are another important growth factors in angiogenesis, wound healing and embryonic development. The FGFs are heparin-binding proteins and interactions with cell surface-associated heparin sulfated proteoglycans. FGF-FGFR-1 is the most common signaling pathway. It has been reported that vacation could stimulate the expression of FGF2, followed by phosphorylation of FGFR-1 and promote angiogenesis in microvascular endothelial cells ([@B74]). Up-regulated FGF2/an early growth response protein 1(EGR1) ameliorated cardiac ischemia and systolic dysfunction ([@B73]). Endothelial FGFR pathways are beneficial for the IHD. Conditional knock out of Fgfr1 and Fgfr2 in endothelial cells attenuated cardiac function compared to control group in myocardial model ([@B43]).

### Angiopoietins

Angiopoietins are parts of vascular growth factors that play an important role in angiogenesis. Angiopoietin cytokines are involved in regulating microvascular permeability and vascular tension. There are four identified angiopoietins: Ang-1, Ang-2, Ang-3, and Ang-4. It has been reported that Ang-1, circulating Ang-2 and Ang-2/Ang-1 ratio (Ang-2/1) were all increased at ST-segment elevation myocardial infarction patients and were related to the serious extend of myocardial damage ([@B15]). Ang-4 could inhibit the activity of lipoprotein lipase which could hydrolyze triglyceride, thus Ang-4 may be related to the low risk of CAD ([@B26]). Ang-2/Tie2 signaling pathway is involved in angiogenesis in inflammatory cornea ([@B83]). Ang-1, miR-1, and miR-206 functioned in hypoxic induced myoblasts vascularization ([@B76]).

Although angiogenic growth factor therapy attracts wide attention, clinical trials for myocardial angiogenesis have produced unstable effects. It is difficult to titer an effective concentration of VEGF in humans and side-effects easily occur. For example, VEGF could increase the permeability of the blood vessels and cause diabetic retina disease. Although, VEGF has been extensively studied further studies are required to gain better efficacy and safety to enable therapeutic angiogenesis.

Gene Therapy
------------

Various improvements in biological vector such as viruses and small DNA have improved transmission and expression efficacy of cytokines to enable clinical to promote angiogenesis ([@B48]). The focus has mainly centered on the use of FGF (FGF1 and FGF2), and VEGF A (VEGF-A165 and VEGF-A121). In preclinical studies, new gene transferring techniques including recombinant adenovirus vectors and liposome complexes have been shown to be effective in promoting angiogenesis for myocardial and vascular diseases ([@B56]). Recombinant adenovirus, co-expressing antimicrobial peptide (PR39) and adrenomedullin (ADM) were injected into infarcted myocardia and attenuated myocardial injury by promoting angiogenesis ([@B2]). However, the robustness and safety of gene therapy really deserve more attention for this to become widely used in clinics.

Stem Cell Therapy
-----------------

Stem cell therapy is also a promising option for treating IHD and has beneficial effects via multiple mechanisms ([@B31]). Autologous bone marrow cells, skeletal myoblasts, embryonic stem cells, adult mesenchymal stem cells (MSCs), and adult hematopoietic progenitor cells all have the potential to treat IHD. Autologous bone marrow cells were transplanted into the ischemic myocardium in five male patients. Cardiac function and blood perfusion were improved demonstrating promising potential for this therapy ([@B84]). Autologous skeletal myoblast transplantation in Phase I clinical studies demonstrated feasibility in treatment of post infarction myocardial injury after 12 months of follow-up, ([@B72]). [@B20] isolated Sprague--Dawley rat hearts in an *ex vivo* Langendorff model and subjected them to ischemia/perfusion treatment. Hearts treated with embryonic stem cells showed better post ischemic recovery ([@B20]). MSCs with activation of Rap1 conferred cardioprotection against myocardial infarction in rats ([@B47]). Likewise, endothelial stem cells and MSCs also improve cardiac function in this case via increasing vascular density ([@B67]). Further studies will be required to determine the optimal cell type, dose, transmission method. Moreover, the ability to treatment time after ischemia will be important to develop the effectiveness of the therapy.

Combined Therapy
----------------

Gene therapy and bone marrow MSCs therapy are commonly combined. [@B66] constructed recombinant adenovirus vectors 5-hERL-IRES-VEGF (Ad5-EIV) combining reporter gene hERL and therapeutic gene VEGF165. The recombinant adenovirus vector was transfected into MSCs (Ad5-EIV-MSCs). In a rat model of myocardial infarction Ad5-EIV-MSCs were transplanted into the peripheral myocardium, effectively preserving cardiac function ([@B66]). Another study also indicated that CXCR4-overexpressing MSCs could repair heart tissue post myocardial infarction by promoting angiogenesis and alleviate left ventricle remodeling via paracrine signaling mechanism ([@B81]).

Chinese Herbal Medicines Targeting Angiogenesis in Ischemic Heart Disease
=========================================================================

Being able to manipulate neovascularization is central to treating IHD. Chinese medicines have a basic view on vascular system for years, such as the concepts of "bloodline and blood-collateral." Bloodline means larger blood vessels and blood-collateral means the smaller vessels. Traditional Chinese medicine believes that Qi is the most basic substance to make up the human body, and Qi and blood are interlinked. Some scholars have identified that Chinese herbal medicines with the action of activating Qi and blood may function in promoting angiogenesis ([@B87]). Increasing evidence has shown Chinese herbal medicines may be effective in the treatment of IHD, especially Chinese medicines with the effects of replenishing and activating blood or invigorating and replenishing Qi. Chinese herbal medicine monomers (**Table [1](#T1){ref-type="table"}**), formula (**Table [2](#T2){ref-type="table"}**) and Chinese patent drugs (**Table [3](#T3){ref-type="table"}**) all have shown some benefit in stimulating revascularization, which is driving further studies for ischemic diseases more widely in China.

###### 

Monomers and active components of medicinal plants in ischemic heart disease.

  Classification                                Name                          Source                           Models               Targets                         Reference
  --------------------------------------------- ----------------------------- -------------------------------- -------------------- ------------------------------- ------------------------
  Replenishing and activating blood             Salvianolic acid A            Radix Salvia miltiorrhiza        *In vivo*            JNK/PI3K/Akt↓; EPCs, MSCs↑      [@B36]; [@B53]; [@B14]
                                                Tanshinone IIA                Radix Salvia miltiorrhiza        *In vivo*            VEGF and HIF-1a↑                [@B82]
                                                Ferulaic acid                 Radix Angelica Sinensis          *In vivo*            VEGF, AKT/mTOR↑                 [@B55]; [@B90]
  Invigorating and replenishing Qi              Rhodiola                      Rhizoma Rhodiolae Kirilowii      *In vivo*            Flt-1, Tie-2, HIF-1a, HIF-1β↑   [@B50]; [@B33]
                                                Salidroside                   Rhizoma Rhodiolae Kirilowii      *In vivo*            Unknown                         [@B88]
                                                Astragalosides                Shanxi Astragalus membranaceus   *In vivo*            VEGF and bFGF↑                  [@B85]
  Other active components of medicinal plants   Berberine                     Berberis and Berberis aristata   *In vivo/in vitro*   miR-29b↑                        [@B92]
                                                Puerarin                      Radix Puerariae                  *In vivo*            VEGF and eNOS↑                  [@B91]
                                                Extract of *Geum japonicum*   Germ japonicum                   *In vivo*            Unknown                         [@B51]

###### 

Chinese herbal formula in ischemic heart disease.

  Name                         Composition                                                                         Models       Results/effects    Reference
  ---------------------------- ----------------------------------------------------------------------------------- ------------ ------------------ -----------
  Danggui Buxue Tang (DBT)     Astragalus, angelica                                                                *In vitro*   Unknown            [@B54]
  Xuefu Zhuyu Tang (XFZYT)     Peach kernel, safflower, angelica, chuanqiong, radix paeoniae rubra                 *In vitro*   VEGF-VEGFR2↑       [@B32]
  Buyang Huanwu Tang (BYHWT)   Astragalus, angelica, radix paeoniae rubrathe, peach kernel, safflower, earthworm   *In vivo*    VEGFR2-PI3K/Akt↑   [@B23]

###### 

Chinese patent drugs in ischemic heart disease.

  Name                      Composition                                                                       Models      Results/effects                       Reference
  ------------------------- --------------------------------------------------------------------------------- ----------- ------------------------------------- ----------------
  Shexiang Baoxin pills     Musk, ginseng extract, bezoar, cinnamon, storax, borneol toad                     *In vivo*   20-HETE, EPCs, and VEGF↑              [@B44]
  QI-SHEN-YI-QI             Astragalus, danshen, panax notoginseng, dalbergia                                 *In vivo*   VEGF, bFGF and PDGF-B↑; miR-223-3p↓   [@B89]; [@B24]
  Tongxinluo                Ginseng, leech, scorpion, centipede, cicada, wood louse insects, red peony root   *In vivo*   PDGF, bFGF, ANG-1, and VEGF↑          [@B22]
  Xuesetong soft capsules   Notoginseng total saponins                                                        *In vivo*   VEGF↑                                 [@B87]

Monomers and Active Components of Medicinal Plants
--------------------------------------------------

### Replenishing and Activating Blood

#### Salvianolic acids

Radix Salvia miltiorrhiza (Danshen) is one of the typical blood-activating and stasis-resolving medicines and it offers therapeutic promise for cardiovascular diseases ([@B77]). Salvianolic acids are the maximum water extraction from Danshen including salvianolic acid A (Sal A) and salvianolic acid B (Sal B). A meta-analysis of five studies was performed to evaluate the effects of Sal A and Sal B on myocardial infarction rats. And it showed that Sal A and Sal B both increased blood vessel density in MI rats ([@B86]). Another trial identified the anti-apoptotic effects of Sal A against ischemic reperfusion injury in diabetic rats. Sal A has similar actions as a JNK inhibitor through down-regulating JNK/PI3K/Akt pathway ([@B14]). Stem cells may be the targets of Sal A and Sal B to improve cardiac function and promote angiogenesis. [@B53] found that Sal A exerted cardioprotection by increasing capillary density in ischemic rat myocardium detected by CD31 staining. Sal A enhanced the activity of endothelial progenitor cells (EPCs) through SDF-1α/CXCR4 axis ([@B53]). *In vitro* experiments showed that Sal B pretreatment could promote MSC differentiated into endothelial cells. Thus injection of Sal B pretreated MSCs improved myocardial infarction in rats by promoting angiogenesis ([@B36]). Taken together, these findings all illustrate that salvianolic acids could effectively promote cardioprotection in pre-clinical models of IHDs.

#### Tanshinone IIA

Vascular endothelial growth factor is a pivotal pro-angiogenic factor. The transcriptional factor, HIF-1 enhances VEGF expression in response to hypoxia and plays an important role relating to angiogenesis ([@B42]). Tanshinone IIA (Tan IIA) is the most abundant diterpene quinone in Danshen. Sodium tanshinone IIA asylate injection is used to treat cardiac infarction in China. Tan IIA elicited significant cardioprotective effects by promoting angiogenesis in MI rat model. Tan IIA improved heart function, reduced infarct size and enhanced VEGF and hypoxia-inducible factor 1alpha (HIF-1) mRNA expression ([@B82]).

#### Ferulaic acid

Ferulaic acid is the main component of Radix Angelica Sinensis. Bone marrow stromal cells (BM-MSCs) play crucial roles in angiogenesis ([@B31]). *In vitro*, BM-MSCs were pre-treated with sodium ferulate and *n*-butylidenephthalide. Then transplantation of pre-treated BM-MSCs into the ischemic stroke zone promoted VEGF production and angiogenesis by AKT/mTOR signaling pathway ([@B90]). [@B55] synthetized a compound called acetyl ferulaic isosorbide (AFI) by the esterification of ferulaic acid and isosorbide mononitrate. AFI showed protective effects in myocardial ischemia/reperfusion (MI/R), however, the protective cellular mechanism have yet to be revealed ([@B55]).

### Invigorating and Replenishing Qi

#### Rhodiola

Rhodiola may relieve MI injury by improving angiogenesis in ischemic myocardium. Rhodiola up-regulated the expression of Flt-1 and Tie-2 in ischemic cardiac zone which are related to angiogenesis ([@B50]). Flt-1, also known as VEGF receptor-1 (VEGFR-1) is a kind of tyrosine kinase. VEGF initiates the angiogenesis process via the activation of VEGFR-1 and VEGFR2 ([@B21]). Tie-2 is the receptor of angiopoietins. Angiopoietins-Ties axis are required for the formation of blood vessels ([@B41]). A different study described in acute myocardial infarction rats, Radix et Rhizoma Rhodiolae Kirilowii may promote angiogenesis through stimulating HIF-1a, HIF-1β and VEGF. The expression of vWF, a marker of endothelial cells was also significantly increased ([@B33]).

#### Salidroside

Salidroside is an active compound extracted from Rhodiola and it has been reported that intramuscular administration of salidroside robustly enhanced blood perfusion recovery in hind-limb ischemia mice ([@B88]). The beneficial effect of salidroside in peripheral artery disease may be extended to use in IHD and would need to be explored further.

#### Astragalosides

Astragaloside (AST), is the total saponin fraction isolated from *Astragalus membranaceus* (Fisch) ([@B78]) and has been used to develop drugs for therapeutics of cardiovascular diseases. AST promoted VEGF and bFGF expression which may contribute to increase in angiogenesis in rat models of myocardial infarction ([@B85]).

### Other Active Components of Medicinal Plants

#### Berberine

Berberine is an alkaloid extracted from *Berberis and Berberis aristata* and has apparent preventive effects on cardiovascular diseases. [@B92] conducted the myocardial infarction (MI) surgery in mice fed with 100 mg/kg/day berberine. Two weeks after surgery, berberine significantly improved cardiac function and increased angiogenesis. Mice treated with berberine had increased expression of miR-29b. The protective effects of berberine were reversed by antagonism of miR-29b in human umbilical endothelial cells *in vitro* ([@B92]). In contrast, reports suggest that miR-29b inhibits angiogenesis by targeting VEGF-A in endometrial carcinoma ([@B13]). MiR-29b also attenuated angiogenesis and tumorigenesis by directly targeting Akt3 ([@B52]) or BCL2L2 ([@B16]). However, the role of miR-29b in angiogenesis may depend upon the cell type and pathophysiological setting such as ischemia.

#### Puerarin

Puerarin is a major effective ingredient extracted from the traditional Chinese medicine ge-gen (radix puerariae). Puerarin treatment (120 mg/kg, i.p.) reduced infarct size and promoted angiogenesis in the ischemic heart of rats with myocardial infarction. The cellular mechanism maybe via promotion of the expression of VEGF and eNOS ([@B91]).

#### Extract of *Geum japonicum*

[@B51] isolated bioactivate fraction from Chinese herb *Geum japonicum*. *In vitro*, they screened and mixed the fractions that could stimulate angiogenesis and cardiomyogenesis. *In vivo*, the mixed fractions decreased infarct size, stimulate early development of new blood vessels and regenerate myocardium ([@B51]).

Chinese Herbal Formula
----------------------

Chinese herbal formula has been reported to be effective in promoting angiogenesis in endothelial cells during intracerebral hemorrhage (REF). Therefore, whether Chinese herbal formula can have protective effects during IHD is yet to be established.

### Danggui Buxue Tang (DBT)

Danggui Buxue Tang (DBT) is a classic Chinese herbal formula which consists of Astragali mongholici Radix and Angelica sinensis Radix (ASR). DBT may enhance angiogenesis and relieve endothelial dysfunction induced by lysophosphatidyl choline ([@B54]).

### Xuefu Zhuyu Tang (XFZYT)

Xuefu Zhuyu Tang (XFZYT) is composed of peach kernel, safflower, angelica, chuanqiong, radix paeoniae rubra and other 11 kinds of natural compounds. XFZYT induced ECV304 endothelial cell proliferation, migration, and angiogenesis by up-regulating VEGF-VEGFR2 pathway. This could potentially explain how XFZYT may have the potential to promote angiogenesis in IHD ([@B32]).

### Buyang Huanwu Tang (BYHWT)

Angiogenesis following intracerebral hemorrhage plays an essential role in maintaining brain functional and ultimately recovery. BYHWT treated mice exhibited increased vessels in the brain and enhanced VEGFR2 phosphorylation in brain micro vessels by PI3K/Akt signaling pathway ([@B23]).

Chinese Patent Drugs
--------------------

### Shexiang Baoxin Pills

Shexiang Baoxin pills (SBPs) may partially participate in angiogenesis. Atherosclerosis and myocardial infarction rabbit models were established by [@B71]. High-fat diet accompanied with SBP was fed. Echocardiography results showed that SBP could improve cardiac functions. CD34 positive staining and increased VEGF and VEGFR-2 expressions indicated that SBP promoted angiogenesis ([@B71]). Another paper dived more deeply into the protective mechanism of SBPs. It may be mediated via up-regulation of 20-hydroxyeicosatetraenoic acid (20-HETE). HET0016 could inhibit the biosynthesis of 20-HETE and it could reverse the protective effects of SBPs on myocardial infarction. What's more, SBP could promote circulating EPCs mobilization and VEGF expression ([@B44]).

### QI-SHEN-YI-QI

QI-SHEN-YI-QI formula consists of astragalus, danshen, panax notoginseng, and dalbergia. Clinically, QI-SHEN-YI-QI formula was widely used to treat angina. Modern pharmacological studies show that QSYQ significantly decreased infarct area, and promoted microvessel density during 7 days in ischemic rats with left anterior descending artery (LAD) ligation. QSYQ treatment group induced the increased mRNA and proteins of VEGF, bFGF and PDGF-B ([@B89]). In microvascular endothelial cells, Dai GH found that Qi-Shen-Yi-Qi Dripping Pills could promote the ECs migration and tube formation. miRNA chip and qPCR techniques were used to analyze the expression of miRNA and found that miR-223-3p was the target of QSYQ ([@B24]).

### Tongxinluo (TXL)

Tongxinluo has the effects of promoting Qi, activating blood and dredging collaterals to relieve pain. Cardiac microvascular endothelial cells (CMECs) stimulated by Tongxinluo secreted more cytokines who were involved in CMECs proliferation, growth and differentiation, as well as chemotaxis and transport in ischemia/reperfusion injury. Among them, PDGF, bFGF, ANG-1, and VEGF all increased which means that Tongxinluo may be associated with angiogenesis ([@B22]).

### Xuesetong Soft Capsules

Xuesetong soft capsules is composed of Notoginseng total Saponins. [@B79] constructed the classical acute myocardial infarction rat models. Xuesetong soft capsules were fed for 6 weeks. Delightingly, Xuesetong soft capsules treatments could accelerate angiogenesis and VEGF mRNA expression in infarcted border zone ([@B79]).

Conclusion
==========

Ischemic heart disease is a serious threat to human health, the incidence is continuously increasing in conjunction with the prevalence of diabetes, metabolic disorders and the aging population. Therapeutic angiogenesis is a promising method in the management of IHD. Accumulating evidence in animal models has demonstrated that blood-activating and stasis-resolving Chinese herbal medicines have pro-angiogenic effects, the mechanisms of which are centered around the vascular growth factor signaling pathway. Nevertheless, further large scale blinded randomized clinical trials are essential to prove the effectiveness of the treatment and clarify our understanding of the therapeutic potential. If the traditional Chinese herbal medicines are to be used alongside contemporary therapy the safety and efficacy of therapeutic angiogenesis deserves more attention. Future studies will need to extend to dosing regime, delivery route and the safety of use alongside current drug therapeutics.

Chinese herbal medicines are apparently effective in the treatment of IHD because of their multi-targeting. However, the exact pro-angiogenic mechanism of Chinese herbal medicines still remains unclear and requires to be fully validated. Without these steps it makes it difficult to extend to the world. At present the understanding of the pro-angiogenic mechanism of Chinese herbal medicines is incomplete, and mainly focuses on the vascular growth factors. Deeper understanding and more specific signaling pathways need to be explored. For example, endothelial cells (ECs) display a highly migratory and proliferative state during vessel sprouting ([@B27]). ECs metabolism are involved in angiogenesis ([@B25]) and it may become a new candidate of Chinese herbal medicines. Inducing stem cells to secret vascular growth factors or form new vessels may be another candidate. In general, to explore the mechanism and effective molecular targets of Chinese herbal medicines are of importance, which will provide new insights into therapeutic angiogenesis and promote the modernization of Chinese herbal medicines.
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